Mayako Uchida

752 total citations
94 papers, 508 citations indexed

About

Mayako Uchida is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Mayako Uchida has authored 94 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 19 papers in Pharmacology. Recurrent topics in Mayako Uchida's work include Pharmaceutical Practices and Patient Outcomes (16 papers), Pharmacy and Medical Practices (16 papers) and Lung Cancer Treatments and Mutations (14 papers). Mayako Uchida is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (16 papers), Pharmacy and Medical Practices (16 papers) and Lung Cancer Treatments and Mutations (14 papers). Mayako Uchida collaborates with scholars based in Japan and United States. Mayako Uchida's co-authors include Yoshihiro Uesawa, Shinya Suzuki, Keiko Hosohata, Takehiro Kawashiri, Tadashi Shimizu, Nobuaki Egashira, Takao Shimazoe, Daisuke Kobayashi, Takayuki Nakagawa and Yukio Suga and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Mayako Uchida

84 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mayako Uchida Japan 14 218 95 74 72 53 94 508
Anne B. Taegtmeyer Switzerland 16 125 0.6× 105 1.1× 40 0.5× 130 1.8× 23 0.4× 50 709
Takahiro Niimura Japan 13 207 0.9× 57 0.6× 34 0.5× 134 1.9× 24 0.5× 67 517
Stefania Mantarro Italy 11 201 0.9× 61 0.6× 24 0.3× 75 1.0× 8 0.2× 17 470
Pauline Bosco‐Lévy France 13 61 0.3× 31 0.3× 23 0.3× 63 0.9× 28 0.5× 31 399
Sophie Fédrizzi France 13 358 1.6× 73 0.8× 17 0.2× 172 2.4× 21 0.4× 49 727
Marie Lund Denmark 15 56 0.3× 97 1.0× 39 0.5× 42 0.6× 34 0.6× 35 709
Marie‐Blanche Valnet‐Rabier France 13 83 0.4× 47 0.5× 20 0.3× 29 0.4× 19 0.4× 28 478
Amandine Gouverneur France 12 121 0.6× 63 0.7× 19 0.3× 60 0.8× 7 0.1× 28 454
Weng-Foung Huang Taiwan 16 104 0.5× 92 1.0× 20 0.3× 22 0.3× 16 0.3× 27 568
Kimitaka Suetsugu Japan 12 135 0.6× 108 1.1× 36 0.5× 71 1.0× 27 0.5× 39 420

Countries citing papers authored by Mayako Uchida

Since Specialization
Citations

This map shows the geographic impact of Mayako Uchida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayako Uchida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayako Uchida more than expected).

Fields of papers citing papers by Mayako Uchida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayako Uchida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayako Uchida. The network helps show where Mayako Uchida may publish in the future.

Co-authorship network of co-authors of Mayako Uchida

This figure shows the co-authorship network connecting the top 25 collaborators of Mayako Uchida. A scholar is included among the top collaborators of Mayako Uchida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayako Uchida. Mayako Uchida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
4.
Kage, M., Hiroyuki Yamakoshi, Kimihiro Noguchi, et al.. (2024). Oxidative generation of isobenzofurans from phthalans: application to the formal synthesis of (±)-morphine. Chemical Science. 15(45). 19070–19076. 3 indexed citations
5.
Uchida, Mayako, Hideki Ochiai, Takehiro Kawashiri, et al.. (2023). Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia. In Vivo. 37(2). 924–932.
6.
Inoue, Satoko, Mayako Uchida, Keiko Fujita, et al.. (2023). Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. JGH Open. 7(2). 87–97. 9 indexed citations
7.
Fujiwara, Masaki, et al.. (2023). Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors. Oncology. 101(5). 343–348. 4 indexed citations
8.
9.
Uchida, Mayako, et al.. (2022). Multicentre prospective observational study on community pharmacist interventions to reduce inappropriate medications. International Journal of Pharmacy Practice. 30(5). 427–433. 5 indexed citations
10.
Fujiwara, Masaki, et al.. (2022). Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database. Oncology. 100(7). 413–418. 3 indexed citations
11.
Fujiwara, Masaki, et al.. (2022). Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. Life. 12(9). 1355–1355. 8 indexed citations
12.
Uchida, Mayako, et al.. (2021). Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database. Oncology. 100(1). 60–64. 13 indexed citations
13.
Uchida, Mayako, et al.. (2021). Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database. Oncology. 100(3). 188–194. 3 indexed citations
14.
Uchida, Mayako, Yuki Yamaguchi, Hiroaki Ikesue, et al.. (2020). Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer. Biological and Pharmaceutical Bulletin. 43(8). 1235–1240. 7 indexed citations
15.
Uchida, Mayako, Yuki Kondo, Shinya Suzuki, & Keiko Hosohata. (2019). Evaluation of Acute Kidney Injury Associated With Anticancer Drugs Used in Gastric Cancer in the Japanese Adverse Drug Event Report Database. Annals of Pharmacotherapy. 53(12). 1200–1206. 19 indexed citations
16.
Uchida, Mayako, Tsutomu Nakamura, Takahiro Shima, et al.. (2019). Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.. PubMed. 74(4). 250–254. 4 indexed citations
17.
Uchida, Mayako, Tsutomu Nakamura, Kojiro Hata, et al.. (2018). Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting. Journal of Pharmaceutical Health Care and Sciences. 4(1). 1–1. 8 indexed citations
18.
Watanabe, Hiroyuki, Hiroaki Ikesue, Kenichiro Nagata, et al.. (2013). Decrease in Venous Irritation by Adjusting the Concentration of Injected Bendamustine. Biological and Pharmaceutical Bulletin. 36(4). 574–578. 3 indexed citations
19.
Tsuji, Toshikazu, et al.. (2012). Pharmaceutical Education Support for Nurses in Pain Management. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 38(4). 237–245.
20.
Kinoshita, Hideki, Mayako Uchida, Hiroyuki Watanabe, et al.. (2010). Investigation of Adverse Drug Reactions in Bortezomib Therapy for Relapsed Multiple Myeloma. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 36(4). 270–276. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026